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Review
Biological role of manganese. Manganese is an 
essential micronutrient that has a broad role 
in macromolecular metabolism. Mn plays a 
role in immune response, blood sugar homeo-
stasis, adenosine triphosphate (ATP) regula-
tion, reproduction, digestion, and bone growth 
(Aschner and Aschner 2005). It is a necessary 
component of metallo  enzymes such as Mn 
superoxide dismutase, arginase, phosphoenol-
pyruvate decarboxylase, and glutamine syn-
thetase (GS) (Aschner and Aschner 2005). GS, 
an enzyme that converts glutamate into gluta-
mine, is thought to be associated with up to 
80% of brain Mn (Prohaska 1987). Mn has 
a heterogeneous distribution throughout the 
brain. In the normal human brain, Mn is most 
concentrated in the globus pallidus, caudate, 
and putamen and is less concentrated in corti-
cal areas (Larsen et al. 1979). Intraneuronal 
axonal transport (Sloot and Gramsbergen 
1994; Takeda et al. 1998b) and potassium-
evoked 54Mn release in rat amygdala (Takeda 
et al. 1998a) demonstrate that Mn may 
participate in neuronal function and neuro-
transmission. Mn can also enter neuronal ter-
minals through calcium channels (Narita et al. 
1990). The consumption of a Mn-deficient 
diet produced seizures in rats, demonstrating 
the importance of Mn in neuronal function 
(Hurley et al. 1963). Mn deficiency, although 
rare, can cause developmental defects includ-
ing malformation of bones, altered macro-
molecular metabolism, and reduced fertility 
(Aschner and Aschner 2005). 
Sources of human exposure. Mn is ubiqui-
tous in the environment. It is present at 0.1% 
in the earth’s crust, and it is also a constituent 
of soil, ranging in concentrations from 40 to 
900 mg/kg (Cooper 1984). It is released into 
the environment as a product of industrial 
activities, the use of the Mn-containing pes-
ticide maneb, and through the use of methyl-
cyclopentadienyl manganese tricarbonyl 
(MMT) as a gasoline antiknock agent (Agency 
for Toxic Substances and Disease Registry 
2000). Mn is present in a variety of foods, 
with the highest concentrations found in 
nuts, legumes, and blueberries (Peterson and 
Skinner 1931). An estimated safe level of daily 
intake is 2–5 mg Mn (for review, see Aschner 
and Aschner 2005).
Increased Mn concentrations in the brain 
can occur from a variety of conditions, with 
contributions to human morbidity stemming 
from occupational, iatrogenic, medical, and 
environmental exposures. Occupational Mn 
exposure is well documented; for example, 
excessive Mn exposure occurs in occupations 
such as ferro  alloy smelting (Bast-Pettersen et al. 
2004; Kaji et al. 1993; Mergler et al. 1994), 
welding (Bowler et al. 2007; Josephs et al. 
2005), mining (Montes et al. 2008; Rodriguez-
Agudelo et al. 2006), battery assembly (Bader 
et al. 1999), and the manufacture of glass and 
ceramics (Srivastava et al. 1991). 
Iatrogenic Mn exposure occurs in indi-
viduals receiving total parenteral nutrition 
(Alves et al. 1997) resulting in increased con-
centrations of Mn in the brain (Reimund et al. 
2000). Further, exposure to at-risk populations 
with compromised or immature blood–brain 
barriers or underdeveloped excretory pathways, 
such as children, can also result in increased 
brain Mn levels after total parenteral nutri-
tion (Iinuma et al. 2003). In support of this 
concept, Mn has been shown to accumulate 
in the brain of postnatal day (PN) 21 rat pups 
to a greater extent than PN70 young adult rats 
after 21 days of oral exposure to Mn (Dorman 
et al. 2000). 
Mn is excreted primarily through the 
bile. Individuals with a decreased capacity 
for biliary Mn excretion also experience Mn 
neuro  toxicity. Increased Mn has been mea-
sured in the blood (Spahr et al. 1996) and 
brains (Burkhard et al. 2003) of individu-
als with cirrhosis. Further, increases in brain 
Mn meas  ured by magnetic resonance imaging 
(MRI) has been documented in patients with 
liver dysfunction (Fukuzawa et al. 2006; Rose 
et al. 1999) and patients with liver failure 
(Aggarwal et al. 2006; Brunberg et al. 1991; 
Klos et al. 2006a).
Recently, Mn exposure has also been asso-
ciated with use of methcathinone (ephedrone) 
contaminated with the oxidant potassium 
permanganate added to the preparation. 
Ephedrone is used intra  venously as a drug of 
abuse, and case reports suggest that the rapid 
onset of hypokinesia, dys  arthria, dystonia, 
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and postural dysfunction in these recreational 
drug users is a product of Mn neuro  toxicity 
(de Bie et al. 2007; Holzgraefe et al. 1986; 
Sanotsky et al. 2007; Sikk et al. 2007). 
The use of MMT as a gasoline antiknock 
agent has raised concerns over potential 
increased environmental exposures of the gen-
eral population to Mn (Kaiser 2003). Elevated 
average indoor and outdoor air concentrations 
of Mn have been reported near expressways in 
Montreal, Quebec, Canada, which uses MMT 
in gasoline, compared with rural communi-
ties in which MMT use is infrequent (Bolte 
et al. 2004). The contribution from the use 
of MMT to environmental levels of Mn to 
humans is an important issue, as an increased 
environmental Mn burden as a consequence 
of Mn generated from MMT-containing 
gasoline and industrial activities may be asso-
ciated with an increased prevalence of move-
ment abnormalities and parkinsonism. 
Toxicologic role. At high levels of expo-
sure, Mn can produce multiple symptoms of 
neurotoxicity. Couper (1837) first described 
progressive motor abnormalities in workers 
occupationally exposed to Mn oxide. Mn poi-
soning has since been associated with an extra-
pyramidal syndrome including kinetic tremor, 
bradykinesia, rigidity, dystonia, and specific 
gait disturbances (Banta and Markesbery 
1977; Cersosimo and Koller 2006; Huang 
et al. 1997). In the absence of continued expo-
sure, motor deficits can persist for many years 
(Bouchard et al. 2007). In addition to these 
motor abnormalities, neuro  psychologic symp-
toms including deficits in working memory, 
concentration, and spatial orientation also 
occur early in Mn neurotoxicity (Josephs et al. 
2005; Klos et al. 2006b; Mergler et al. 1994). 
A study conducted in Bangladesh showed a 
significant association between exposure to 
high levels of Mn in well water and deficits 
in cognitive function assessed by verbal scores 
and measures of intellectual ability of children 
(Wasserman et al. 2006). Importantly, a diag-
nosis of Parkinson disease (PD) at an earlier 
average age was correlated with elevated ambi-
ent Mn concentrations related to industrial 
emissions in a Canadian study (Finkelstein 
and Jerrett 2007). In addition, increased air 
concentrations of Mn derived from mining 
and industrial activities in Mexico were sta-
tistically significantly associated with deficits 
in movement coordination and hand posi-
tion changes (Rodriguez-Agudelo et al. 2006). 
Further, an increased prevalence of PD in a 
population in Brescia, Italy, was associated 
with increased Mn concentrations in settled 
dust resulting from nearby ferro  alloy plants 
(Lucchini et al. 2007). 
Toxicokinetics. Mn is known to have 
11 oxidation states (Takeda 2003), although 
only two oxidation states—Mn2+ and Mn3+—
are common in biological systems (Archibald 
and Tyree 1987). Mn2+ is the most stable, 
although Mn3+ most efficiently oxidizes intra-
cellular substrates such as dopa  mine (Archibald 
and Tyree 1987). Mn3+ binds to and is trans-
ported by transferrin (Aschner et al. 2007), 
whereas it is postulated that Mn2+ must use 
other transporter systems to enter cells (Takeda 
2003). Gastrointestinal absorption and inhala-
tion are the two main routes by which Mn is 
absorbed into the human body. 
Approximately 1–5% of gastrointestinal 
Mn is absorbed (Davis et al. 1993). Sixty to 
70% of inhaled Mn is expelled from the lung 
by mucocilliary movement and is swallowed 
(Mena 1974), although Mn absorption also 
occurs directly in the lung (Vitarella et al. 
2000). Importantly, Mn can be transported 
directly into the brain during inhalation via 
the olfactory tract (Dorman et al. 2002). Mn is 
mainly excreted through the bile (Davis et al. 
1993). Under normal conditions, Mn con-
centrations in the blood are between 0.8 and 
2.1 µg/L (Dobson et al. 2004). After excessive 
Mn exposures, average blood Mn levels have 
been documented at 10–40 µg/L (Takser et al. 
2003), but maximum reported values from 
one study measured blood Mn in newborns 
at approximately 90 µg/L and in the birthing 
mother approximately 150 µg/L (Takser et al. 
2003). In blood, Mn is present as a free ion 
(Takeda 2003), and it is also bound to serum 
proteins and metal binding proteins such as 
transferrin (Aschner and Aschner 2005). 
Mn enters the brain at the capillary 
endothelium across the choroid plexus (Rabin 
et al. 1993). Calcium has been shown to play 
an important role in the regulation of Mn 
transport at the blood–brain barrier (Crossgrove 
and Yokel 2005). Additionally, divalent metal 
ion transporter 1 (DMT1)-mediated transport 
(Au et al. 2008), the N-methyl-d-aspartate 
(NMDA) receptor channel (Itoh et al. 2008), 
transferrin (Aschner and Gannon 1994), dif-
fusion, and active transport (Rabin et al. 1993) 
also contribute to Mn transport across the 
blood–brain barrier (for review, see Aschner 
et al. 2007). The importance of the transferrin 
pathway in brain uptake of Mn is underscored 
by observations of increased Mn levels in the 
brains of rats following iron deficiency, which 
up-regulates transferrin-mediated transport 
(Aschner 2000). 
Once Mn has crossed the blood–brain 
barrier, the average half-life of Mn in the rat 
brain is 51–74 days (Takeda et al. 1995). 
In nonhuman primates, available data sug-
gest that the rate of elimination in the brain 
has region specificity; however, estimates of 
half-life range from ≤ 33 days (Dorman et al. 
2006a) to 53 days (Newland et al. 1987) after 
inhalational and subcutaneous Mn exposure, 
respectively. The normal concentration of 
Mn in the brain is, on average, 0.26 µg/g wet 
weight (Markesbery et al. 1984), although 
Mn distribution throughout the brain is 
known to be heterogeneous. In nonhuman 
primates chronically exposed to Mn by intra-
venous injection and inhalation, Mn has 
been observed to accumulate throughout 
the brain in vivo using T1-weighted MRI 
(Dorman et al. 2006b; Guilarte et al. 2006b). 
The region of the brain in which Mn accu-
mulates to the greatest extent is the globus 
pallidus. Using inhalation as a route of expo-
sure, Dorman et al. (2006a) demonstrated 
that the globus pallidus accumulates Mn 
concentrations in a dose-dependent fashion 
and ranges from 1.6- to 6.0-fold relative to 
control animals after occupationally relevant 
exposures. An intravenous injection paradigm 
of Mn exposure produced an approximately 
5-fold increase in pallidal Mn concentrations 
(Guilarte et al. 2006b). 
Mn can be taken up into astrocytes and 
neurons. Erikson and Aschner (2006) showed 
that astrocytic uptake of Mn takes place at 
least in part via DMT1. Neuronal uptake of 
Mn involves transferrin (Suarez and Eriksson 
1993) as well as utilization of specific trans-
porter systems such as the dopamine trans-
porter (DAT) (Anderson et al. 2007; Chen 
et al. 2006b). Intra  cellularly, Mn accumulates 
in the mitochondria (Gavin et al. 1999), and 
Mn accumulation in the nucleus has been 
demonstrated (Kalia et al. 2008). Utilization 
of divalent cation transporters such as the 
calcium uniporter (Gavin et al. 1999) and the 
positive valence of Mn ion may explain the 
localization of Mn to electron-rich mitochon-
dria. Axonal transport of Mn occurs (Sloot 
and Gramsbergen 1994), which contributes 
to the observations of elevated concentra-
tions of Mn efferent to iron-rich regions of 
the brain that have high concentrations of the 
transferrin receptor (Dobson et al. 2004). 
Bock et al. (2008) recently compared 
the pharmaco  kinetics of Mn entry into and 
distribution throughout the brain in rodents 
and non  human primates as measured by 
T1-weighted MRI. That study demon-
strated that for a given dose, Mn transport 
into nonhuman primate brain is greater than 
the absorption into the brain of rodents. 
Additionally, these authors demonstrated that 
the distribution of Mn throughout the brain 
differs between nonhuman primates and 
rodents. Bock et al. (2008) explained these 
differences between species as a product of 
Mn transport from the cerebro  spinal fluid at 
the choroid plexus into the brain. The differ-
ences in brain anatomy between rodents and 
non  human primates and differential position-
ing of brain regions such as the striatum rela-
tive to brain ventricles may drive the unique 
patterns of regional accumulation of Mn 
described in rodents and nonhuman primates. 
The similarities in brain structure between 
nonhuman primates and humans offer the Manganese neurotoxicity in nonhuman primates
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opportunity to study Mn neurotoxicity in an 
animal model that recapitulates the pattern of 
human brain Mn accumulation. 
Mechanisms of Toxicity
Mitochondrial respiration. The disruption of 
mitochondrial activity by Mn is well docu-
mented. Mn2+ uses the calcium uniporter 
to gain entrance into mitochondria (Gavin 
et al. 1999). In the mitochondria, the bulk 
of Mn is bound to the inner mitochondrial 
membrane or matrix proteins (Gavin et al. 
1999). This allows Mn to directly interact 
with proteins involved in oxidative phos-
phorylation. Mn has been shown in vitro to 
interfere with ATP synthesis (Gunter et al. 
2006), particularly by inhibiting the func-
tion of the F1ATPase (Gavin et al. 1992) 
and at higher concentrations by inhibiting 
complex I (Chen et al. 2001). Importantly, 
the speciation of Mn is a critical determi-
nant of its inter  actions. Trivalent Mn inhibits 
complex I more potently than does divalent 
Mn (Chen et al. 2001), and Mn3+ more effi-
ciently oxidizes intra  cellular substrates such 
as dopamine (Archibald and Tyree 1987). 
However,   divalent Mn is the predominant 
species found in tissue (Gunter et al. 2006). 
Mn has been associated with suppression of 
ATP-dependent calcium waves in astrocytes, 
suggesting that Mn promotes the potentially 
disruptive mitochondrial sequestration of cal-
cium (Tjalkens et al. 2006). Nuclear mag-
netic resonance spectroscopy has been used 
in culture to show that Mn decreases ATP/
adenosine diphosphate ratios and impairs glu-
cose metabolism and metabolic activity in the 
globus pallidus (Zwingmann et al. 2007). 
Oxidative stress. The generation of reac-
tive oxygen species is intimately linked to 
mitochondrial activities, and there is much 
evidence to support the role of reactive oxy-
gen species in Mn neurotoxicity. Rats treated 
with Mn for 7 days by oral gavage showed 
increased striatal concentrations of ascorbic 
acid and gluta  thione (GSH), anti  oxidants 
that when increased signal the presence of an 
elevated burden from reactive oxygen species 
(Desole et al. 1994). A later study conducted 
in rats exposed to Mn by inhalation confirmed 
the presence of markers of oxidative stress, 
with decreased GSH and increased metallo-
thionine in the Mn-exposed animals (Dobson 
et al. 2003). Nonhuman primate studies fur-
ther substantiated the association between 
Mn exposure and increases in metallothi-
onine and decreases in GSH (Erikson et al. 
2007). Addition of Mn to cultured astrocytes 
increases 2´,7´-dichloro  fluoro  scein fluores-
cence indicative of increased reactive oxygen 
species, and coincubation of N-acetylcysteine 
blocks Mn toxicity (Chen and Liao 2002). 
Not only has Mn exposure been asso-
ciated with markers of oxidative stress, but 
activation of signaling pathways involved 
in the response to oxidative stress has been 
documented as well. In PC12 cells, Mn 
induced the expression of nuclear factor 
kappa B (NFκB) (Ramesh et al. 2002) and 
AP-1 (Wise et al. 2004), further providing 
support for an oxidative basis in Mn neuro-
toxicity. Pretreatment with either vitamin 
E or a NFκB inhibitor has been shown to 
protect against Mn toxicity in mesencephalic 
cells (Prabhakaran et al. 2008). The intracel-
lular consequences of Mn-induced increases 
in oxidative stress are becoming clearer as we 
learn more about the mechanisms of Mn neu-
rotoxicity. Recent studies have shown that in 
dopaminergic cells, Mn can promote apop-
tosis by a caspase 3–dependent activation of 
protein kinase C delta (Latchoumycandane 
et al. 2005). Mn neuro  toxicity may involve 
oxidative stress and apoptosis, intercon-
nected pathways that have been linked to the 
pathophysiology of neuro  degenerative disease 
(Tansey et al. 2007). Microarray data from 
the frontal cortex of Mn-exposed nonhuman 
primates shows that the expression of genes 
involved in apoptosis and inflammation is 
increased relative to control animals (Guilarte 
et al. 2008a). 
Dopaminergic synapses. Much research 
has endeavored to describe the mechanisms 
by which Mn produces adverse motor func-
tion outcomes reminiscent of idiopathic 
PD. Because Mn-exposed individuals often 
exhibit motor symptoms such as kinetic 
tremor and dystonia (Cersosimo and Koller 
2006) not typically associated with PD and 
because Mn-exposed individuals generally do 
not respond to levodopa therapy (Lu et al. 
1994), the gold standard for PD treatment, 
it is believed that Mn neurotoxicity involves 
pathologic mechanisms distinct from those 
of PD. Available human autopsy data suggest 
that the nigro  striatal system is not degenerated 
after Mn exposure (Perl and Olanow 2007). 
Mn may cause dysfunction of the dopamine 
neuronal terminal that may set the stage for 
susceptibility to a later insult. However, the 
evidence for Mn-induced dopaminergic neu-
ronal dysfunction is incomplete. It is known 
that in vitro Mn can promote auto  oxidation 
of dopa  mine, which leads to the creation of 
reactive dopa  mine quinones (Miller et al. 
1990; Shen and Dryhurst 1998). However, 
early rodent data offer conflicting evidence 
on the influence of Mn exposure on cate-
cholamine concentrations (Bonilla and Prasad 
1984; Chandra and Shukla 1981; Eriksson 
et al. 1987a; Gianutsos and Murray 1982; 
Komura and Sakamoto 1994). In nonhuman 
primates, high cumulative exposures to Mn 
> 300 mg/kg show reduced striatal concentra-
tions of dopamine (Bird et al. 1984; Eriksson 
et al. 1987b; Neff et al. 1969); however, stud-
ies using lower doses have demonstrated no 
effect of Mn on dopamine levels (Olanow 
et al. 1996; Struve et al. 2007). Additional 
evidence from nonhuman primate data sug-
gests a Mn-induced post  synaptic decrease of 
D2-like dopamine receptor levels (Eriksson 
et al. 1992). However, the limited number of 
studies that have examined the effect of Mn 
in the context of chronic exposure leave the 
relationship between Mn, the dopaminergic 
system, and the development of motor dys-
function an open question.
Glutamatergic synapses. There is a per-
sistent notion in the literature that a compo-
nent of Mn neurotoxicity may be modified 
by dys  regulation of excitatory glutamatergic 
neurotransmission. Increased glutamate levels 
in the brain have been documented in rodents 
exposed to Mn (Gwiazda et al. 2002; Lipe 
et al. 1999; Reaney et al. 2006). Zwingmann 
et al. (2007) showed that Mn increases gluta-
mate in some areas such as the frontal cortex 
but decreases it in the globus pallidus, but 
additional research suggests that glutamate 
levels are not affected by Mn exposure in 
rodents (Bonilla et al. 1994). These inconsis-
tencies are most likely a consequence of varied 
Mn doses, routes of administration, dosing 
intervals and durations, species-based differ-
ences in pharmaco  kinetics, and differences 
in the brain regions analyzed. In vitro studies 
have implicated Mn in the reduction of glu-
tamate transporter expression (Erikson and 
Aschner 2002; Mutkus et al. 2005) and astro-
cytic glutamate uptake (Hazell and Norenberg 
1997). These alterations could negatively 
impact synaptic glutamate metabolism and 
distribution. Additional limited data are avail-
able on the effect of chronic Mn exposure 
in non  human primates and its effects on the 
glutamatergic systems. However, available 
evidence suggests that nonhuman primates 
exposed to Mn via inhalation for 13 weeks 
did not have altered glutamate levels in the 
globus pallidus, caudate, and putamen (Struve 
et al. 2007) but did express increased mRNA 
expression and decreased protein levels of 
GLAST and GLT, the two main astrocytic 
glutamate transporters, and GS, the enzyme 
that converts glutamate into glutamine, in 
multiple brain regions (Erikson et al. 2007). 
GABAergic synapses. Evidence for the 
involvement of GABAergic systems in Mn 
neurotoxicity stems from early observations 
that Mn exposure in rodents increases stri-
atal GABA (γ-aminobutyric acid) concentra-
tions (Bonilla 1978). Later studies showed 
that chronic Mn administration to rodents 
produced an increase in striatal GABA con-
centrations (Gianutsos and Murray 1982) 
and abolished age-dependent declines in 
  glutamic acid decarboxylase (Lai et al. 1981), 
the enzyme that converts glutamate to 
GABA. Additional rodent studies further sup-
ported an association between Mn exposure Burton and Guilarte
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and increased brain GABA concentrations 
(Gwiazda et al. 2002; Lipe et al. 1999; Reaney 
et al. 2006). However, other rodent studies 
complicated this picture by showing that Mn 
decreases striatal and frontal cortex GABA 
levels (Brouillet et al. 1993; Seth et al. 1981). 
Moreover, other rodent studies show no asso-
ciation between GABA levels and Mn expo-
sure (Bonilla et al. 1994). Little information is 
available regarding the GABAergic system in 
the context of Mn exposure in nonhuman pri-
mates. One study available in rhesus monkeys 
chronically exposed to Mn by inhalation indi-
cates that in multiple brain regions Mn does 
not alter GABA levels (Struve et al. 2007). 
Another study that used monthly injections of 
Mn oxide in nonhuman primates for 2 years 
showed no effect of Mn on GABAa receptor 
levels (Eriksson et al. 1992). 
Glial cells. Accumulating evidence indi-
cates that Mn may indirectly affect neuronal 
function by damaging glial cells. Autopsy data 
from humans exposed to Mn indicate the 
presence of astrocyte activation in the brain 
(for review, see Perl and Olanow 2007). These 
associations have been recapitulated in animal 
models. Astrogliosis and Alzheimer type II 
astrocytes have been demonstrated in nonhu-
man primates treated acutely (Pentschew et al. 
1963) and chronically (Guilarte et al. 2008a; 
Olanow et al. 1996) with Mn. In cultured 
astrocytes treated with Mn, cellular swelling 
was observed within 24 hr of Mn exposure 
(Rama Rao et al. 2007). Further, Mn disrupts 
intracellular calcium homeo  stasis and inter-
cellular calcium waves in primary astrocytes 
(Tjalkens et al. 2006). Increased inducible 
nitric oxide synthase (iNOS) mRNA and 
protein and increased release of nitric oxide 
have also been observed after Mn exposure 
in primary astrocytes (Spranger et al. 1998), 
microglial cells (Bae et al. 2006), mesen-
cephalic cells (Prabhakaran et al. 2008), and 
Mn-exposed mice (Liu et al. 2006). The 
nitric oxide pathway is intimately linked with 
NMDA receptor-mediated excitotoxic pro-
cesses and microglial activation (Dawson et al. 
1991; Hewett et al. 1994). One group has 
demonstrated in cultured astrocytes (Erikson 
and Aschner 2002), in rodents (Erikson et al. 
2004), and in nonhuman primates (Erikson 
et al. 2007) that Mn exposure causes a 
decrease in astrocytic glutamate transporters 
and the astrocytic enzyme GS. 
Microglia are also affected by Mn expo-
sure. Microglial cells treated with Mn readily 
release hydrogen peroxide (Zhang et al. 2007). 
In rats treated acutely with Mn, Hazell et al. 
(2003) observed an increase in the trans  locator 
protein (18 kilodaltons) (TSPO-18kDa) (pre-
viously known as the peripheral benzodiaz-
epine receptor). In the brain, TSPO-18kDa 
is a microglial and astrocytic protein that has 
been used as a marker of gliosis and is useful in 
identifying areas of brain injury and inflamma-
tion (Chen and Guilarte 2008). An increase in 
proinflammatory genes such as tumor necrosis 
factor-α, iNOS, and activated inflammatory 
proteins such as P-p38, P-ERK, and P-JNK 
have been meas  ured in primary rat glial cells 
after Mn exposure (Chen et al. 2006a). Mn 
also potentiates lipopolysaccharide-induced 
increases in proinflammatory cytokines in 
microglial cultures (Filipov et al. 2005) and 
increases in nitric oxide production (Chang 
and Liu 1999). This association between Mn 
exposure and inflammatory gene expression is 
supported by microarray data from the frontal 
cortex of Mn-exposed nonhuman primates 
that show that chronic Mn exposure increases 
of the expression of inflammatory genes such 
as osteopontin and the interferon-γ receptor 
(Guilarte et al. 2008a). 
Chronic Mn Neurotoxicity in 
Nonhuman Primates
Much of the available data that inform our 
understanding of the mechanisms of Mn neu-
rotoxicity is derived from rodent studies. Little 
work has been comprehensively conducted 
analyzing the effects of chronic Mn exposure 
in nonhuman primates. We have analyzed one 
of the largest cohorts of nonhuman primates 
ever used to study chronic Mn neuro  toxicity. 
Experiments are still under way; however, the 
available data thus far support the involvement 
of dopaminergic nigrostriatal dysfunction, 
selective astrocytic modulation of glutamate 
processing in the globus pallidus, and multiple 
indices of neuro  toxicity in brain regions not 
generally associated with Mn exposure. Here, 
we summarize the findings from behavioral, 
neuro  imaging, and neuro  pathologic studies 
that provide important insights on mechanisms 
suggested by previous studies and more path-
ways not previously thought to be operational 
in Mn neuro  toxicity. The average blood Mn 
concentrations of the animals we used were in 
the 65–85 µg/L range (Guilarte et al. 2006a, 
2008b). This concentration is within the upper 
range of blood Mn concentrations documented 
in human populations such as those living near 
Mn mining areas (Santos-Burgoa et al. 2001), 
in mothers and newborns (Takser et al. 2003) 
and in children in communities in which 
MMT is used in gasoline (Gulson et al. 2006), 
and as a result of parenteral nutrition (Iinuma 
et al. 2003).
Cognition and behavior. Because 
humans exposed to high levels of Mn expe-
rience behavioral abnormalities (Mergler 
and Baldwin 1997) and cognitive deficits 
(Lucchini et al. 1995), we sought to charac-
terize the involvement of behavioral and cog-
nitive disturbances in nonhuman primates 
exposed to 3.3–5.0 mg Mn/kg/week for 
approximately 10 months (Schneider et al. 
2006). Animals (cynomolgus macaques) 
were trained on a series of tasks that meas  ure 
behavior and cognitive performance. After 
approximately 20 weeks of exposure and con-
tinuing throughout the duration of the study, 
the Mn-exposed animals developed a small 
but statistically significant increase in the rate 
of PD-like behaviors on a scale developed to 
assess parkinsonian behaviors in non  human 
primates (Schneider and Kovelowski 1990). 
Fine motor skills were assessed by an easy 
task and by a difficult task. Although Mn 
exposure had no effect on the easy task, by 
the end of the observation period the animals 
performed poorly on the difficult task. These 
observations are consistent with documenta-
tion of humans exposed to Mn occupation-
ally or as a consequence of treatment with 
total parenteral nutrition who suffer cogni-
tive deficits (Josephs et al. 2005; Klos et al. 
2006b; Mergler et al. 1994) and also perform 
poorly on tests of fine motor ability (Shin 
et al. 2007). The Mn-exposed animals also 
expressed stereotypic and compulsive-like 
behaviors that may be explained by involve-
ment of dysfunctional frontostriatal circuitry. 
Magnetic resonance spectroscopy. Few data 
are available that comprehensively charac-
terize Mn neurotoxicity throughout the 
brain, especially in the context of chronic 
exposure in nonhuman primates. Therefore, 
we used 1H-magnetic resonance spectros-
copy (1H-MRS) to longitudinally assess the 
potential toxic effects of chronic Mn expo-
sure on levels of brain metabolites (Guilarte 
et al. 2006b) that are thought to reflect vari-
ous aspects of neuronal and glial functioning 
in the brain (Jenkins and Kraft 1999). The 
concentrations of the brain metabolites crea-
tine, N-acetylaspartate (NAA), choline, and 
myo-inositol were characterized by 1H-MRS 
in the parietal cortex, striatum, thalamus, 
and frontal white matter. The globus pallidus 
could not be assessed because the iron content 
interferes with acquisition of the 1H-MRS 
signal. Data were normalized to creatine con-
tent in a particular brain region. NAA is a 
neuron-specific metabo  lite, myo-inositol is 
used as a glial cell marker, and choline is a 
substituent of cell membranes (De Stefano 
et al. 2007). Reductions in NAA/creatine are 
reflective of neuronal loss and/or dysfunc-
tion, alterations in myo-inosi  tol/crea  tine are 
suggestive of glial activation or damage, and 
modulation of choline/creatine can provide 
important information on membrane phos-
pholipids in the context of myelin break-
down. Whereas the ratio of choline/crea  tine 
and myo-inositol/creatine were unchanged 
by chronic Mn exposure, the ratio of NAA/
crea  tine was significantly reduced in the 
parie  tal cortex of Mn-exposed animals rela-
tive to baseline. A near-significant (p = 0.055) 
decrease was observed in frontal white matter. 
Reduced NAA levels also occur in pathologic Manganese neurotoxicity in nonhuman primates
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conditions such as stroke and Alzheimer’s 
disease (Kantarci 2007), and the reduction 
of NAA is reflective of neuronal dysfunc-
tion or degenera  tion. The in vivo analy  sis of 
Mn-exposed animals by MRS further under-
scores observations that although Mn accu-
mulates to the greatest extent in the globus 
pallidus, other regions of the brain that may 
accumulate Mn to a lesser extent can still be 
vulnerable to Mn neurotoxicity. 
Dopaminergic synapses. Given the simi-
larities in some of the symptoms of Mn 
intoxi  cation and the clinical symptoms of 
PD, as well as available supporting animal 
research implicating the dopaminergic system 
in Mn neurotoxicity, we have characterized 
multiple aspects of the dopaminergic synapse 
in nonhuman primates exposed to Mn both 
acutely and chronically using positron emis-
sion tomography (PET) and ex vivo methods. 
In an early study (Chen et al. 2006b), we 
examined the effect of acute Mn exposure on 
DAT levels in baboons as assessed by PET 
and post  mortem analysis. Acute Mn expo-
sure caused a transient increase in DAT levels 
within 1 week of exposure that normalized 
after approximately 1 month. Further, it was 
shown that Mn inhibits [3H]-dopamine uptake 
in rat stria  tal synaptosomes. Although Mn has 
no effect on the affinity (Kd) of the cocaine 
analog [3H]-WIN 35,428 binding to DAT, we 
observed a statistically significant 30% reduc-
tion of the Bmax, indicating that although Mn 
has no effect of the affinity of the DAT ligand, 
it reduces the available number of binding sites. 
This suggested that Mn may affect the presyn-
aptic dopaminergic neuronal terminal through 
modulation of DAT function and levels. 
We have also used neuroimaging and 
neuro  pathologic techniques to comprehen-
sively probe the effect of chronic Mn exposure 
in cynomolgus macaques on multiple param-
eters of the dopaminergic synapse (Guilarte 
et al. 2006a, 2008b). The most dramatic 
change observed with chronic Mn exposure 
was a reduction in the capacity of striatal dop-
amine release, measured by PET with amphet-
amine (AMPH) challenge. Importantly, an 
animal receiving the highest dose of Mn (8.3–
10.0 mg/kg/week) that expressed dystonia and 
dyskinesias also exhibited the largest decline in 
AMPH-induced dopa  mine release from a base-
line of 44% to 8.0% release after only 7 weeks 
of Mn exposure (Guilarte et al. 2008b). These 
findings indicate that Mn-induced motor 
function deficits are caused by mechanisms 
that inhibit dopa  mine release in the presence 
of normal levels of dopa  mine and an intact 
nigrostriatal dopa  mine system. This view is 
in contrast to theories suggesting that Mn 
neuro  toxicity is mediated by an effect on post-
synaptic dopamine receptors. 
Importantly, the use of control animals 
that received no Mn but did receive repeated 
AMPH injections as part of the PET imaging 
protocol provided insight on the activity of Mn 
at the dopaminergic synapse. Although AMPH 
administration was necessary to charac  terize 
the in vivo capacity for dopamine release by 
PET, AMPH itself causes alterations in the 
integrity of dopaminergic neuronal terminals. 
However, this image-control group showed 
greater deficits in DAT, vesicular mono  amine 
transporter type 2, and dopamine and its 
metabolites relative to Mn-exposed animals 
that received equivalent amounts of AMPH 
normalized to body weight. This suggests 
that Mn may directly inter  act with DAT and 
interfere with AMPH uptake into dopamin-
ergic neurons. This is consistent with previ-
ously published reports that Mn is a substrate 
for DAT (Anderson et al. 2007; Ingersoll 
et al. 1999) and that Mn inhibits binding of 
a cocaine analog to DAT and inhibits dopa-
mine uptake in striatal synaptosomes (Chen 
et al. 2006b). These findings strongly suggest 
that the documented motor function abnor-
malities in Mn-exposed nonhuman primates at 
Mn doses given in this study are mediated by 
inhibition of dopa  mine release in the striatum 
and shed new light on the molecular basis of 
Mn-induced parkinsonism.
Glutamatergic/GABAergic synapses. 
Evidence of the involvement of the glutamate 
and GABA neurotransmitter systems can be 
traced back three decades and involves stud-
ies conducted in primary cell culture models, 
rodents, and nonhuman primates. However, 
the culture and rodent data has been contra-
dictory and inconclusive (see “Glutamatergic 
synapses” and “GABAergic synapses” above). 
Until recently, little information has been 
available in nonhuman primates on glutamate 
and GABA neuro  trans  mission throughout the 
brain. Therefore, we also recently studied the 
effect of Mn on glutamatergic and GABAergic 
systems throughout the nonhuman primate 
brain. Chronic Mn exposure did not alter glu-
tamate, GABA, or the glycine (a coagonist for 
NMDA glutamate receptors) levels in frontal 
white matter, globus pallidus, caudate, puta-
men, hippocampus, thalamus, cortex (frontal, 
motor, somatosensory, parietal, visual), cer-
ebellar lobules, and deep cerebellar nucleus 
(Burton NC, unpublished data). These find-
ings are consistent with a recent report that 
suggested that chronic Mn exposure in nonhu-
man primates does not alter the concentration 
of glutamate or GABA in the globus pallidus, 
caudate, or putamen (Struve et al. 2007). In 
our recent study (Burton NC, unpublished 
data), Mn did not consistently promote a 
change in levels of NMDA receptors, GABAa 
receptors, or glutamate transporters. However, 
Mn did cause a reduction in GS in the globus 
pallidus, a glial-specific enzyme that converts 
glutamate into glutamine as part of the glu-
tamate recycling process. The decrease in GS 
levels in Mn-exposed nonhuman primates is 
consistent with observations made in another 
cohort of nonhuman primates exposed 
to Mn via inhalation (Erikson et al. 2007). 
Reductions in GS levels can cause dysregula-
tion of the glutamate recycling pathway, and 
by mass action, a reduction in the conversion 
of glutamate into glutamine could lead to an 
increase in intra  cellular glutamate concentra-
tions in astrocytes and a potential spillover 
into the synapse with the potential to cause 
excitotoxicity in the globus pallidus. 
Frontal cortex. The neurologic sequelae 
of exposure to high levels of Mn occur in 
multiple stages. The early phase of Mn intoxi-
cation involves a psychiatric component, char-
acterized in part by irritability, apathy, and 
psychosis, and is sometimes called Mn mania 
(Mergler and Baldwin 1997). Deficits in 
meas  ures of executive function, such as short-
term memory and computational ability, are 
also early manifestations of Mn neurotoxic-
ity (Lucchini et al. 1995). Studies show that 
Mn accumulates in the frontal cortex (Bock 
et al. 2008; Dorman et al. 2006a; Guilarte 
et al. 2008a), and it has been suggested that 
Mn may alter cognitive domains mediated by 
the frontal cortex and subcortical structures 
(Josephs et al. 2005). Toward this end, we 
performed micro  array analysis of frontal cortex 
tissue from naïve control animals and animals 
exposed to 3.3–5.0 mg Mn/week (Guilarte 
et al. 2008a). The results indicated that Mn 
promoted modulation of genes related to 
inflammation, apoptosis, cell cycle, protein 
turnover and folding, synaptic function, and 
cholesterol homeostasis. These observations 
suggested that Mn may promote inflammation 
and cell death in the frontal cortex. Further, 
the activation of cell cycle machinery in post-
mitotic cells such as neurons disrupts nor-
mal cellular processes and has been implicated 
in dysfunction and cell death in Alzheimer’s 
disease (Raina et al. 2000; Yang et al. 2003). 
An imbalance in cholesterol homeostasis is 
associated with the development of patho-
logic processes present in Alzheimer’s disease 
(Puglielli et al. 2003). In addition, the most 
highly up-regulated gene was amyloid beta 
(A4) precursor-like protein 1 (APLP1), which 
is a member of the amyloid precursor pro-
tein involved in copper homeostasis and the 
regulation of the toxic peptide beta amyloid 
(Aβ)1-42 (Neumann et al. 2006). The increase 
in APLP1 gene expression was confirmed by 
immuno  histo  chemistry and led to the fur-
ther analysis of Aβ levels in the frontal cortex. 
Unexpectedly, in the juvenile animals used 
in this study, extracellular diffuse aggregation 
of Aβ was observed in the frontal cortex of 
Mn-exposed animals, a condition normally 
observed in the aged brain. This suggested that 
Mn accelerates the aging process and promotes 
Alzheimer’s-like neuro  pathology in the frontal Burton and Guilarte
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cortex. The presence of neuro  degenerative 
changes in the frontal cortex of Mn-exposed 
animals was confirmed by the presence of 
neuronal agyrophilic inclusions using silver 
staining and by morphologic changes consis-
tent with apoptotic stigmata (Guilarte et al. 
2008a). Neurons of the frontal cortex of 
Mn-exposed animals expressed hyper  trophic 
nuclei and vacuolar cell bodies suggestive of 
ongoing pathology. Hydroxynonenol staining, 
a marker of lipid peroxidation, was associ-
ated with apoptotic cells. Astrogliosis was also 
observed in the Mn-exposed animals. APLP1 
is regulated by the tumor suppressor p53 
(Tang et al. 2007), as are many of the genes 
identified in the microarray analysis. Increased 
p53 and APLP1 staining co-localized with 
cells showing morphologically apoptotic fea-
tures, suggesting the possibility that Mn may 
function through p53 to affect changes in 
APLP1 that promote extracellular Aβ accumu-
lation. In addition, Mn exposure also caused 
an increase of approximately 30% in copper 
concentrations in the frontal cortex (Guilarte 
et al. 2008a). Accumulation of brain copper 
has been associated with Aβ plaques in the AD 
brain (Bush 2003). Dysregulation of copper 
homeostasis may be one additional mechanism 
by which Mn promotes neurodegenerative 
processes. Further studies are warranted in 
an appropriate cell culture system to deter-
mine the mechanistic relationship among Mn 
exposure, p53 levels and activity, APLP1, Aβ, 
and copper homeostasis. The gene expression 
changes and markers of neurodegeneration in 
the frontal cortex may help to explain not only 
the subtle cognitive deficits previously charac-
terized in these Mn-exposed animals, but also 
some of the early manifestations of Mn neuro-
toxicity in humans related to working memory 
and neuropsychiatric behaviors. 
Conclusion
Much of the research that has informed the 
understanding of the mechanisms of Mn 
neuro  toxicity is based on data generated from 
cell culture and research conducted in rodents. 
Possible mechanisms suggested by rodent data 
must be confirmed in higher species, especially 
in light of recent pharmaco  kinetic studies sug-
gesting that brain Mn uptake and distribution 
may be dramatically different between primates 
and rodents (Bock et al. 2008). Unfortunately, 
studies conducted in non  human primates are 
few. The multi  disciplinary study described 
within is the largest cohort of nonhuman pri-
mates that has been used to characterize the 
effects of chronic Mn exposure throughout 
the brain on neuroimaging, pathology, mul-
tiple neurotransmitter systems, behavior, and 
cognition. These data provide corroborative 
support that chronic Mn exposure does not 
alter total levels of dopamine, glutamate, or 
GABA. However, Mn may reduce GS levels 
and produce a glial-specific effect on the glu-
tamatergic system in the globus pallidus by 
interfering with the recycling of glutamate, 
which may ultimately promote a redistribu-
tion of glutamate at the synapse. Additionally, 
PET studies demonstrated that Mn produces 
its most substantial effect on the nigro  striatal 
dopamine system not by producing its degen-
eration, but by disrupting the capacity to 
release dopamine. Last, MRS documented 
neuronal loss and/or dysfunction in the pari-
etal cortex, and postmortem analysis showed 
neuro  degeneration in the frontal cortex. These 
cortical regions were previously unsuspected to 
be involved in Mn neuro  toxicity because they 
accumulate relatively low levels of Mn com-
pared with the globus pallidus. These findings 
indicate that Mn neurotoxicity is not simply 
defined by the amount of Mn that a brain 
region accumulates but by the intrinsic vulner-
ability to injury by Mn. 
Therefore, the continuum of dysfunction 
caused by Mn from psychiatric to cognitive 
to motor abnormalities cannot be explained 
by dysregulation of basal ganglia structures 
alone. These findings suggest that historical 
views of Mn neurotoxicity should be revisited 
to account for the spectrum of Mn-induced 
neurologic dysfunction. 
RefeRences
Agency for Toxic Substances and Disease Registry. 2000. 
Toxicological Profile for Manganese. Available: http://www.
atsdr.cdc.gov/toxprofiles/tp151.html [accessed 1 June 2008].
Aggarwal A, Vaidya S, Shah S, Singh J, Desai S, Bhatt M. 2006. 
Reversible parkinsonism and T1W pallidal hyperintensities 
in acute liver failure. Mov Disord 21:1986–1990.
Alves G, Thiebot J, Tracqui A, Delangre T, Guedon C, Lerebours E. 
1997. Neurologic disorders due to brain manganese deposi-
tion in a jaundiced patient receiving long-term parenteral 
nutrition. JPEN J Parenter Enteral Nutr 21:41–45.
Anderson JG, Cooney PT, Erikson KM. 2007. Inhibition of DAT 
function attenuates manganese accumulation in the globus 
pallidus. Environ Toxicol Pharmacol 23:179–184.
Archibald FS, Tyree C. 1987. Manganese poisoning and the 
attack of trivalent manganese upon catecholamines. Arch 
Biochem Biophys 256:638–650.
Aschner JL, Aschner M. 2005. Nutritional aspects of manganese 
homeostasis. Mol Aspects Med 26:353–362.
Aschner M. 2000. Manganese: brain transport and emerg-
ing research needs. Environ Health Perspect 108(suppl 
3):429–432.
Aschner M, Gannon M. 1994. Manganese (Mn) transport across 
the rat blood-brain barrier: saturable and transferrin- 
dependent transport mechanisms. Brain Res Bull 33:345–349.
Aschner M, Guilarte TR, Schneider JS, Zheng W. 2007. 
Manganese: recent advances in understanding its transport 
and neurotoxicity. Toxicol Appl Pharmacol 221:131–147.
Au C, Benedetto A, Aschner M. 2008. Manganese transport in 
eukaryotes: the role of DMT1. Neurotoxicology 29:569–576.
Bader M, Dietz MC, Ihrig A, Triebig G. 1999. Biomonitoring of 
manganese in blood, urine and axillary hair following low-
dose exposure during the manufacture of dry cell batteries. 
Int Arch Occup Environ Health 72:521–527.
Bae JH, Jang BC, Suh SI, Ha E, Baik HH, Kim SS, et al. 2006. 
Manganese induces inducible nitric oxide synthase 
(iNOS) expression via activation of both MAP kinase and 
PI3K/Akt pathways in BV2 microglial cells. Neurosci Lett 
398:151–154.
Banta RG, Markesbery WR. 1977. Elevated manganese lev-
els associated with dementia and extrapyramidal signs. 
Neurology 27:213–216.
Bast-Pettersen R, Ellingsen DG, Hetland SM, Thomassen Y. 
2004. Neuropsychological function in manganese alloy 
plant workers. Int Arch Occup Environ Health 77:277–287.
Bird ED, Anton AH, Bullock B. 1984. The effect of manganese 
inhalation on basal ganglia dopamine concentrations in 
rhesus monkey. Neurotoxicology 5:59–65.
Bock NA, Paiva FF, Nascimento GC, Newman JD, Silva AC. 2008. 
Cerebrospinal fluid to brain transport of manganese in a non-
human primate revealed by MRI. Brain Res 1198:160–170.
Bolte S, Normandin L, Kennedy G, Zayed J. 2004. Human exposure 
to respirable manganese in outdoor and indoor air in urban 
and rural areas. J Toxicol Environ Health A 67:459–467.
Bonilla E. 1978. Increased GABA content in caudate nucleus 
of rats after chronic manganese chloride administration. 
J Neurochem 31:551–552.
Bonilla E, Arrieta A, Castro F, Davila JO, Quiroz I. 1994. 
Manganese toxicity: free amino acids in the striatum and 
olfactory bulb of the mouse. Invest Clin 35:175–181.
Bonilla E, Prasad AL. 1984. Effects of chronic manganese intake 
on the levels of biogenic amines in rat brain regions. 
Neurobehav Toxicol Teratol 6:341–344.
Bouchard M, Mergler D, Baldwin M, Panisset M, Bowler R, 
Roels HA. 2007. Neurobehavioral functioning after cessa-
tion of manganese exposure: a follow-up after 14 years. 
Am J Ind Med 50:831–840.
Bowler RM, Nakagawa S, Drezgic M, Roels HA, Park RM, 
Diamond E, et al. 2007. Sequelae of fume exposure in con-
fined space welding: a neurological and neuropsychological 
case series. Neurotoxicology 28:298–311.
Brouillet EP, Shinobu L, McGarvey U, Hochberg F, Beal MF. 
1993. Manganese injection into the rat striatum produces 
excitotoxic lesions by impairing energy metabolism. Exp 
Neurol 120:89–94.
Brunberg JA, Kanal E, Hirsch W, Van Thiel DH. 1991. Chronic 
acquired hepatic failure: MR imaging of the brain at 1.5 T. 
AJNR Am J Neuroradiol 12:909–914.
Burkhard PR, Delavelle J, Du PR, Spahr L. 2003. Chronic par-
kinsonism associated with cirrhosis: a distinct subset 
of acquired hepatocerebral degeneration. Arch Neurol 
60:521–528.
Bush AI. 2003. The metallobiology of Alzheimer’s disease. 
Trends Neurosci 26:207–214.
Cersosimo MG, Koller WC. 2006. The diagnosis of manganese-
induced parkinsonism. Neurotoxicology 27:340–346.
Chandra SV, Shukla GS. 1981. Concentrations of striatal cate-
cholamines in rats given manganese chloride through 
drinking water. J Neurochem 36:683–687.
Chang JY, Liu LZ. 1999. Manganese potentiates nitric oxide pro-
duction by microglia. Brain Res Mol Brain Res 68:22–28.
Chen CJ, Liao SL. 2002. Oxidative stress involves in astrocytic 
alterations induced by manganese. Exp Neurol 175:216–225.
Chen CJ, Ou YC, Lin SY, Liao SL, Chen SY, Chen JH. 2006a. 
Manganese modulates pro-inflammatory gene expression 
in activated glia. Neurochem Int 49:62–71.
Chen JY, Tsao GC, Zhao Q, Zheng W. 2001. Differential cyto-
toxicity of Mn(II) and Mn(III): special reference to mito-
chondrial [Fe-S] containing enzymes. Toxicol Appl 
Pharmacol 175:160–168.
Chen MK, Guilarte TR. 2008. Translocator protein 18 kDa 
(TSPO): molecular sensor of brain injury and repair. 
Pharmacol Ther 118:1–17.
Chen MK, Lee JS, McGlothan JL, Furukawa E, Adams RJ, 
Alexander M, et al. 2006b. Acute manganese administra-
tion alters dopamine transporter levels in the non-human 
primate striatum. Neurotoxicology 27:229–236.
Cooper WC. 1984. The health implications of increased manga-
nese in the environment resulting from the combustion of 
fuel additives: a review of the literature. J Toxicol Environ 
Health 14:23–46.
Couper J. 1837. On the effects of black oxide of manganese 
when inhaled into the lungs. Br Ann Med Pharm Vital Stat 
Gen Sci 1:41–42.
Crossgrove JS, Yokel RA. 2005. Manganese distribution across 
the blood-brain barrier. IV. Evidence for brain influx 
through store-operated calcium channels. Neurotoxicology 
26:297–307.
Davis CD, Zech L, Greger JL. 1993. Manganese metabolism in 
rats: an improved methodology for assessing gut endog-
enous losses. Proc Soc Exp Biol Med 202:103–108.
Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH. 1991. 
Nitric oxide mediates glutamate neurotoxicity in primary 
cortical cultures. Proc Natl Acad Sci USA 88:6368–6371.
de Bie RM, Gladstone RM, Strafella AP, Ko JH, Lang AE. 2007. 
Manganese-induced Parkinsonism associated with meth-
cathinone (ephedrone) abuse. Arch Neurol 64:886–889.Manganese neurotoxicity in nonhuman primates
Environmental Health Perspectives  •  v o l u m e  117 | n u m b e r 3 | March 2009  331
De Stefano N, Filippi M, Miller D, Pouwels PJ, Rovira A, Gass A, 
et al. 2007. Guidelines for using proton MR spectroscopy in 
multicenter clinical MS studies. Neurology 69:1942–1952.
Desole MS, Miele M, Esposito G, Migheli R, Fresu L, de Natale G, 
et al. 1994. Dopaminergic system activity and cellular 
defense mechanisms in the striatum and striatal synapto-
somes of the rat subchronically exposed to manganese. 
Arch Toxicol 68:566–570.
Dobson AW, Erikson KM, Aschner M. 2004. Manganese neuro-
toxicity. Ann N Y Acad Sci 1012:115–128.
Dobson AW, Weber S, Dorman DC, Lash LK, Erikson KM, 
Aschner M. 2003. Oxidative stress is induced in the rat 
brain following repeated inhalation exposure to manganese 
sulfate. Biol Trace Elem Res 93:113–126.
Dorman DC, Brenneman KA, McElveen AM, Lynch SE, 
Roberts KC, Wong BA. 2002. Olfactory transport: a direct 
route of delivery of inhaled manganese phosphate to the 
rat brain. J Toxicol Environ Health A 65:1493–1511.
Dorman DC, Struve MF, Marshall MW, Parkinson CU, James RA, 
Wong BA. 2006a. Tissue manganese concentrations in 
young male rhesus monkeys following subchronic manga-
nese sulfate inhalation. Toxicol Sci 92:201–210.
Dorman DC, Struve MF, Vitarella D, Byerly FL, Goetz J, Miller R. 
2000. Neurotoxicity of manganese chloride in neonatal and 
adult CD rats following subchronic (21-day) high-dose oral 
exposure. J Appl Toxicol 20:179–187.
Dorman DC, Struve MF, Wong BA, Dye JA, Robertson ID. 2006b. 
Correlation of brain magnetic resonance imaging changes 
with pallidal manganese concentrations in rhesus monkeys 
following subchronic manganese inhalation. Toxicol Sci 
92:219–227.
Erikson K, Aschner M. 2002. Manganese causes differen-
tial regulation of glutamate transporter (GLAST) taurine 
transporter and metallothionein in cultured rat astrocytes. 
Neurotoxicology 23:595–602.
Erikson KM, Aschner M. 2006. Increased manganese uptake 
by primary astrocyte cultures with altered iron status 
is mediated primarily by divalent metal transporter. 
Neurotoxicology 27:125–130.
Erikson KM, Dobson AW, Dorman DC, Aschner M. 2004. 
Manganese exposure and induced oxidative stress in the 
rat brain. Sci Total Environ 334–335:409–416.
Erikson KM, Dorman DC, Lash LH, Aschner M. 2007. Manganese 
inhalation by rhesus monkeys is associated with brain 
regional changes in biomarkers of neurotoxicity. Toxicol 
Sci 97:459–466.
Eriksson H, Gillberg PG, Aquilonius SM, Hedstrom KG, 
Heilbronn E. 1992. Receptor alterations in manganese 
intoxicated monkeys. Arch Toxicol 66:359–364.
Eriksson H, Lenngren S, Heilbronn E. 1987a. Effect of long-term 
administration of manganese on biogenic amine levels in 
discrete striatal regions of rat brain. Arch Toxicol 59:426–431.
Eriksson H, Magiste K, Plantin LO, Fonnum F, Hedstrom KG, 
Theodorsson-Norheim E, et al. 1987b. Effects of manga-
nese oxide on monkeys as revealed by a combined neuro-
chemical, histological and neurophysiological evaluation. 
Arch Toxicol 61:46–52.
Filipov NM, Seegal RF, Lawrence DA. 2005. Manganese poten-
tiates in vitro production of proinflammatory cytokines and 
nitric oxide by microglia through a nuclear factor kappa 
B-dependent mechanism. Toxicol Sci 84:139–148.
Finkelstein MM, Jerrett M. 2007. A study of the relationships 
between Parkinson’s disease and markers of traffic-
derived and environmental manganese air pollution in two 
Canadian cities. Environ Res 104:420–432.
Fukuzawa T, Matsutani S, Maruyama H, Akiike T, Saisho H, 
Hattori T. 2006. Magnetic resonance images of the globus 
pallidus in patients with idiopathic portal hyper  tension: 
a quantitative analysis of the relationship between 
signal intensity and the grade of portosystemic shunt. 
J Gastroenterol Hepatol 21:902–907.
Gavin CE, Gunter KK, Gunter TE. 1992. Mn2+ sequestration by 
mitochondria and inhibition of oxidative phosphorylation. 
Toxicol Appl Pharmacol 115:1–5.
Gavin CE, Gunter KK, Gunter TE. 1999. Manganese and calcium 
transport in mitochondria: implications for manganese 
toxicity. Neurotoxicology 20:445–453.
Gianutsos G, Murray MT. 1982. Alterations in brain dopamine 
and GABA following inorganic or organic manganese 
administration. Neurotoxicology 3:75–81.
Guilarte TR, Burton NC, Verina T, Prabhu VV, Becker KG, 
Syversen T, et al. 2008a. Increased APLP1 expression and 
neurodegeneration in the frontal cortex of manganese-
exposed non-human primates. J Neurochem 105:1948–1959.
Guilarte TR, Burton NC, McGlothan JL, Verina T, Zhou Y, 
Alexander M, et al. 2008b. Impairment of nigrostriatal dop-
amine neurotransmission by manganese is mediated by 
pre-synaptic mechanism(s): implications to manganese-
induced parkinsonism. J Neurochem 107:1236–1247. 
Guilarte TR, Chen MK, McGlothan JL, Verina T, Wong DF, Zhou Y, 
et al. 2006a. Nigrostriatal dopamine system dysfunction and 
subtle motor deficits in manganese-exposed non-human 
primates. Exp Neurol 202:381–390.
Guilarte TR, McGlothan JL, Degaonkar M, Chen MK, Barker PB, 
Syversen T, et al. 2006b. Evidence for cortical dysfunction 
and widespread manganese accumulation in the non  human 
primate brain following chronic manganese exposure: a 
1H-MRS and MRI study. Toxicol Sci 94:351–358.
Gulson B, Mizon K, Taylor A, Korsch M, Stauber J, Davis JM, 
et al. 2006. Changes in manganese and lead in the environ-
ment and young children associated with the introduc-
tion of methylcyclopentadienyl manganese tricarbonyl in 
gasoline—preliminary results. Environ Res 100:100–114.
Gunter TE, Gavin CE, Aschner M, Gunter KK. 2006. Speciation of 
manganese in cells and mitochondria: a search for the proxi-
mal cause of manganese neurotoxicity. Neurotoxicology 
27:765–776.
Gwiazda RH, Lee D, Sheridan J, Smith DR. 2002. Low cumula-
tive manganese exposure affects striatal GABA but not 
dopamine. Neurotoxicology 23:69–76.
Hazell AS, Norenberg MD. 1997. Manganese decreases gluta  mate 
uptake in cultured astrocytes. Neurochem Res 22:1443–1447.
Hazell  AS,  Normandin  L,  Nguyen  B,  Kennedy  G.  2003. 
Upregulation of ‘peripheral-type’ benzodiazepine receptors 
in the globus pallidus in a sub-acute rat model of manga-
nese neurotoxicity. Neurosci Lett 349:13–16.
Hewett SJ, Csernansky CA, Choi DW. 1994. Selective potentia-
tion of NMDA-induced neuronal injury following induction 
of astrocytic iNOS. Neuron 13:487–494.
Holzgraefe M, Poser W, Kijewski H, Beuche W. 1986. Chronic 
enteral poisoning caused by potassium permanganate: a 
case report. J Toxicol Clin Toxicol 24:235–244.
Huang CC, Chu NS, Lu CS, Calne DB. 1997. Cock gait in manga-
nese intoxication. Mov Disord 12:807–808.
Hurley LS, Wooley DE, Rosenthal F, Timiras PS. 1963. Influence 
of manganese on susceptibility of rats to convulsions. Am 
J Physiol 204:493–496.
Iinuma Y, Kubota M, Uchiyama M, Yagi M, Kanada S, Yamazaki 
S, et al. 2003. Whole-blood manganese levels and brain 
manganese accumulation in children receiving long-term 
home parenteral nutrition. Pediatr Surg Int 19:268–272.
Ingersoll RT, Montgomery EB Jr, Aposhian HV. 1999. Central 
nervous system toxicity of manganese. II: Cocaine or 
reserpine inhibit manganese concentration in the rat 
brain. Neurotoxicology 20:467–476.
Itoh K, Sakata M, Watanabe M, Aikawa Y, Fujii H. 2008. The entry 
of manganese ions into the brain is accelerated by the acti-
vation of N-methyl-d-aspartate receptors. Neuroscience 
154:732–740.
Jenkins BG, Kraft E. 1999. Magnetic resonance spectroscopy 
in toxic encephalopathy and neurodegeneration. Curr 
Opin Neurol 12:753–760.
Josephs KA, Ahlskog JE, Klos KJ, Kumar N, Fealey RD, Trenerry 
MR, et al. 2005. Neurologic manifestations in welders with 
pallidal MRI T1 hyperintensity. Neurology 64:2033–2039.
Kaiser J. 2003. Manganese: a high-octane dispute. Science 
300:926–928.
Kaji H, Ohsaki Y, Rokujo C, Higashi T, Fujino A, Kamada T. 1993. 
Determination of blood and urine manganese (Mn) con-
centrations and the application of static sensography as 
the indices of Mn-exposure among Mn-refinery workers. 
J UOEH 15:287–296.
Kalia K, Jiang W, Zheng W. 2008. Manganese accumulates 
primarily in nuclei of cultured brain cells. Neurotoxicology 
29(3):466–470.
Kantarci K. 2007. 1H magnetic resonance spectroscopy in 
dementia. Br J Radiol 80(Spec No 2):S146–S152.
Klos KJ, Ahlskog JE, Kumar N, Cambern S, Butz J, Burritt 
M, et al. 2006a. Brain metal concentrations in chronic 
liver failure patients with pallidal T1 MRI hyperintensity. 
Neurology 67:1984–1989.
Klos KJ, Chandler M, Kumar N, Ahlskog JE, Josephs KA. 2006b. 
Neuropsychological profiles of manganese neurotoxicity. 
Eur J Neurol 13:1139–1141.
Komura J, Sakamoto M. 1994. Chronic oral administration of 
methylcyclopentadienyl manganese tricarbonyl altered 
brain biogenic amines in the mouse: comparison with 
inorganic manganese. Toxicol Lett 73:65–73.
Lai JC, Leung TK, Lim L. 1981. Brain regional distribution of 
glutamic acid decarboxylase, choline acetyltransferase, 
and acetylcholinesterase in the rat: effects of chronic 
manganese chloride administration after two years. 
J Neurochem 36:1443–1448.
Larsen NA, Pakkenberg H, Damsgaard E, Heydorn K. 1979. 
Topographical distribution of arsenic, manganese, and sele-
nium in the normal human brain. J Neurol Sci 42:407–416.
Latchoumycandane C, Anantharam V, Kitazawa M, Yang Y, 
Kanthasamy A, Kanthasamy AG. 2005. Protein kinase Cδ 
is a key downstream mediator of manganese-induced 
apoptosis in dopaminergic neuronal cells. J Pharmacol 
Exp Ther 313:46–55.
Lipe GW, Duhart H, Newport GD, Slikker W Jr, Ali SF. 1999. 
Effect of manganese on the concentration of amino acids 
in different regions of the rat brain. J Environ Sci Health B 
34:119–132.
Liu X, Sullivan KA, Madl JE, Legare M, Tjalkens RB. 2006. 
Manganese-induced neurotoxicity: the role of astroglial-
derived nitric oxide in striatal interneuron degeneration. 
Toxicol Sci 91:521–531.
Lu CS, Huang CC, Chu NS, Calne DB. 1994. Levodopa failure in 
chronic manganism. Neurology 44:1600–1602.
Lucchini R, Selis L, Folli D, Apostoli P, Mutti A, Vanoni O, et al. 
1995. Neurobehavioral effects of manganese in workers 
from a ferroalloy plant after temporary cessation of expo-
sure. Scand J Work Environ Health 21:143–149.
Lucchini RG, Albini E, Benedetti L, Borghesi S, Coccaglio R, 
Malara EC, et al. 2007. High prevalence of Parkinsonian dis-
orders associated to manganese exposure in the vicinities 
of ferroalloy industries. Am J Ind Med 50:788–800.
Markesbery WR, Ehmann WD, Hossain TI, Alauddin M. 1984. 
Brain manganese concentrations in human aging and 
Alzheimer’s disease. Neurotoxicology 5:49–57.
Mena I. 1974. The role of manganese in human disease. Ann 
Clin Lab Sci 4:487–491.
Mergler D, Baldwin M. 1997. Early manifestations of manganese 
neurotoxicity in humans: an update. Environ Res 73:92–100.
Mergler D, Huel G, Bowler R, Iregren A, Belanger S, Baldwin M, 
et al. 1994. Nervous system dysfunction among workers with 
long-term exposure to manganese. Environ Res 64:151–180.
Miller DM, Buettner GR, Aust SD. 1990. Transition metals as 
catalysts of “autoxidation” reactions. Free Radic Biol Med 
8:95–108.
Montes S, Riojas-Rodriguez H, Sabido-Pedraza E, Rios C. 2008. 
Biomarkers of manganese exposure in a population living 
close to a mine and mineral processing plant in Mexico. 
Environ Res 106:89–95.
Mutkus L, Aschner JL, Fitsanakis V, Aschner M. 2005. The 
in vitro uptake of glutamate in GLAST and GLT-1 trans-
fected mutant CHO-K1 cells is inhibited by manganese. 
Biol Trace Elem Res 107:221–230.
Narita K, Kawasaki F, Kita H. 1990. Mn and Mg influxes through 
Ca channels of motor nerve terminals are prevented by 
verapamil in frogs. Brain Res 510:289–295.
Neff NH, Barrett RE, Costa E. 1969. Selective depletion of 
caudate nucleus dopamine and serotonin during chronic 
manganese dioxide administration to squirrel monkeys. 
Experientia 25:1140–1141.
Neumann S, Schobel S, Jager S, Trautwein A, Haass C, Pietrzik 
CU, et al. 2006. Amyloid precursor-like protein 1 influences 
endocytosis and proteolytic processing of the amyloid 
precursor protein. J Biol Chem 281:7583–7594.
Newland MC, Cox C, Hamada R, Oberdorster G, Weiss B. 1987. 
The clearance of manganese chloride in the primate. 
Fundam Appl Toxicol 9:314–328.
Olanow CW, Good PF, Shinotoh H, Hewitt KA, Vingerhoets F, 
Snow BJ, et al. 1996. Manganese intoxication in the rhesus 
monkey: a clinical, imaging, pathologic, and biochemical 
study. Neurology 46:492–498.
Pentschew A, Ebner FF, Kovatch RM. 1963. Experimental man-
ganese encephalopathy in monkeys. A preliminary report. 
J Neuropathol Exp Neurol 22:488–499.
Perl DP, Olanow CW. 2007. The neuropathology of manganese-
induced Parkinsonism. J Neuropathol Exp Neurol 66:675–682.
Peterson WH, Skinner JT. 1931. Distribution of manganese in 
food. J Nutr 4:419–426.
Prabhakaran K, Ghosh D, Chapman GD, Gunasekar PG. 2008. 
Molecular mechanism of manganese exposure-induced 
dopaminergic toxicity. Brain Res Bull 76:361–367.
Prohaska JR. 1987. Functions of trace elements in brain metabo-
lism. Physiol Rev 67:858–901.
Puglielli L, Tanzi RE, Kovacs DM. 2003. Alzheimer’s disease: the 
cholesterol connection. Nat Neurosci 6:345–351.Burton and Guilarte
332  v o l u m e  117 | n u m b e r 3 | March 2009  •  Environmental Health Perspectives
Rabin O, Hegedus L, Bourre JM, Smith QR. 1993. Rapid brain 
uptake of manganese(II) across the blood-brain barrier. 
J Neurochem 61:509–517.
Raina AK, Zhu X, Rottkamp CA, Monteiro M, Takeda A, Smith MA. 
2000. Cyclin’ toward dementia: cell cycle abnormalities and 
abortive oncogenesis in Alzheimer disease. J Neurosci Res 
61:128–133.
Rama Rao KV, Reddy PV, Hazell AS, Norenberg MD. 2007. 
Manganese induces cell swelling in cultured astrocytes. 
Neurotoxicology 28:807–812.
Ramesh GT, Ghosh D, Gunasekar PG. 2002. Activation of early 
signaling transcription factor, NF-kappaB following low-
level manganese exposure. Toxicol Lett 136:151–158.
Reaney SH, Bench G, Smith DR. 2006. Brain accumulation 
and toxicity of Mn(II) and Mn(III) exposures. Toxicol Sci 
93:114–124.
Reimund JM, Dietemann JL, Warter JM, Baumann R, Duclos 
B. 2000. Factors associated to hypermanganesemia in 
patients receiving home parenteral nutrition. Clin Nutr 
19:343–348.
Rodriguez-Agudelo Y, Riojas-Rodriguez H, Rios C, Rosas I, 
Sabido PE, Miranda J, et al. 2006. Motor alterations asso-
ciated with exposure to manganese in the environment in 
Mexico. Sci Total Environ 368:542–556.
Rose C, Butterworth RF, Zayed J, Normandin L, Todd K, 
Michalak A, et al. 1999. Manganese deposition in basal 
ganglia structures results from both portal-systemic shunt-
ing and liver dysfunction. Gastroenterology 117:640–644.
Sanotsky Y, Lesyk R, Fedoryshyn L, Komnatska I, Matviyenko Y, 
Fahn S. 2007. Manganic encephalopathy due to “ephedrone” 
abuse. Mov Disord 22:1337–1343.
Santos-Burgoa C, Rios C, Mercado LA, Arechiga-Serrano R, 
Cano-Valle F, Eden-Wynter RA, et al. 2001. Exposure to 
manganese: health effects on the general population, a 
pilot study in central Mexico. Environ Res 85:90–104.
Schneider JS, Decamp E, Koser AJ, Fritz S, Gonczi H, Syversen 
T, et al. 2006. Effects of chronic manganese exposure on 
cognitive and motor functioning in non-human primates. 
Brain Res 1118:222–231.
Schneider JS, Kovelowski CJ. 1990. Chronic exposure to low 
doses of MPTP. I. Cognitive deficits in motor asymptomatic 
monkeys. Brain Res 519:122–128.
Seth PK, Hong JS, Kilts CD, Bondy SC. 1981. Alteration of cerebral 
neurotransmitter receptor function by exposure of rats to 
manganese. Toxicol Lett 9:247–254.
Shen XM, Dryhurst G. 1998. Iron- and manganese-catalyzed 
autoxidation of dopamine in the presence of l-cysteine: 
possible insights into iron- and manganese-mediated 
dopa  minergic neurotoxicity. Chem Res Toxicol 11:824–837.
Shin YC, Kim E, Cheong HK, Cho S, Sakong J, Kim KS, et al. 
2007. High signal intensity on magnetic resonance imaging 
as a predictor of neurobehavioral performance of workers 
exposed to manganese. Neurotoxicology 28:257–262.
Sikk K, Taba P, Haldre S, Bergquist J, Nyholm D, Zjablov G, et al. 
2007. Irreversible motor impairment in young addicts—
ephedrone, manganism or both? Acta Neurol Scand 
115:385–389.
Sloot WN, Gramsbergen JB. 1994. Axonal transport of manga-
nese and its relevance to selective neurotoxicity in the rat 
basal ganglia. Brain Res 657:124–132.
Spahr L, Butterworth RF, Fontaine S, Bui L, Therrien G, Milette 
PC, et al. 1996. Increased blood manganese in cirrhotic 
patients: relationship to pallidal magnetic resonance signal 
hyperintensity and neurological symptoms. Hepatology 
24:1116–1120.
Spranger M, Schwab S, Desiderato S, Bonmann E, Krieger D, 
Fandrey J. 1998. Manganese augments nitric oxide synthe-
sis in murine astrocytes: a new pathogenetic mechanism in 
manganism? Exp Neurol 149:277–283.
Srivastava AK, Gupta BN, Mathur N, Murty RC, Garg N, 
Chandra SV. 1991. An investigation of metal concentrations 
in blood of industrial workers. Vet Hum Toxicol 33:280–282.
Struve MF, McManus BE, Wong BA, Dorman DC. 2007. Basal 
ganglia neurotransmitter concentrations in rhesus monkeys 
following subchronic manganese sulfate inhalation. Am J 
Ind Med 50:772–778.
Suarez N, Eriksson H. 1993. Receptor-mediated endocytosis of 
a manganese complex of transferrin into neuroblastoma 
(SHSY5Y) cells in culture. J Neurochem 61:127–131.
Takeda A. 2003. Manganese action in brain function. Brain Res 
Brain Res Rev 41:79–87.
Takeda A, Ishiwatari S, Okada S. 1998a. In vivo stimulation-
induced release of manganese in rat amygdala. Brain Res 
811:147–151.
Takeda A, Kodama Y, Ishiwatari S, Okada S. 1998b. Manganese 
transport in the neural circuit of rat CNS. Brain Res Bull 
45:149–152.
Takeda A, Sawashita J, Okada S. 1995. Biological half-lives of 
zinc and manganese in rat brain. Brain Res 695:53–58.
Takser L, Mergler D, Hellier G, Sahuquillo J, Huel G. 2003. 
Manganese, monoamine metabolite levels at birth, and child 
psychomotor development. Neurotoxicology 24:667–674.
Tang X, Milyavsky M, Goldfinger N, Rotter V. 2007. Amyloid-
beta precursor-like protein APLP1 is a novel p53 transcrip-
tional target gene that augments neuroblastoma cell death 
upon genotoxic stress. Oncogene 26:7302–7312.
Tansey MG, McCoy MK, Frank-Cannon TC. 2007. Neuro-
inflammatory mechanisms in Parkinson’s disease: potential 
environmental triggers, pathways, and targets for early 
therapeutic intervention. Exp Neurol 208:1–25.
Tjalkens RB, Zoran MJ, Mohl B, Barhoumi R. 2006. Manganese 
suppresses ATP-dependent intercellular calcium waves 
in astrocyte networks through alteration of mitochondrial 
and endoplasmic reticulum calcium dynamics. Brain Res 
1113:210–219.
Vitarella D, Wong BA, Moss OR, Dorman DC. 2000. Pharmaco-
kinetics of inhaled manganese phosphate in male Sprague-
Dawley rats following subacute (14-day) exposure. Toxicol 
Appl Pharmacol 163:279–285.
Wasserman GA, Liu X, Parvez F, Ahsan H, Levy D, Factor-Litvak P, 
et al. 2006. Water manganese exposure and children’s intel-
lectual function in Araihazar, Bangladesh. Environ Health 
Perspect 114:124–129.
Wise K, Manna S, Barr J, Gunasekar P, Ramesh G. 2004. 
Activation of activator protein-1 DNA binding activity due 
to low level manganese exposure in pheochromocytoma 
cells. Toxicol Lett 147:237–244.
Yang Y, Mufson EJ, Herrup K. 2003. Neuronal cell death is 
preceded by cell cycle events at all stages of Alzheimer’s 
disease. J Neurosci 23:2557–2563.
Zhang P, Hatter A, Liu B. 2007. Manganese chloride stimulates 
rat microglia to release hydrogen peroxide. Toxicol Lett 
173:88–100.
Zwingmann C, Leibfritz D, Hazell AS. 2007. Nmr spectroscopic 
analysis of regional brain energy metabolism in manganese 
neurotoxicity. Glia 55:1610–1617.